Slow release of basic fibroblast growth factor (b-FGF) promotes growth of tracheal cartilage

J Pediatr Surg. 2013 Feb;48(2):288-92. doi: 10.1016/j.jpedsurg.2012.11.003.

Abstract

Purpose: Tracheomalacia is a major cause of morbidity in conditions such as oesophageal atresia. However, symptoms usually improve with age. A more rapid growth of tracheal cartilage can be induced by basic-Fibroblast Growth Factor (b-FGF). This study aimed to investigate whether slow-release b-FGF could act as a novel treatment for tracheomalacia.

Methods: Biodegradable gelatin hydrogel sheets incorporating 0.5, 5, or 50 μg/20 μl of b-FGF solution were inserted between the cervical trachea and esophagus of rats. No intervention was performed in rats in a control group. All animals were sacrificed 4 weeks later, and the luminal area of the cervical trachea and the thickness of the cartilage were measured.

Results: The mean luminal areas in the control group and in the b-FGF groups were 3.1, 3.2, 3.8, and 2.6mm(2), respectively, and showed a peak area at 5 μg of b-FGF. A significant difference was seen only between the control group and the b-FGF 5 μg group (p<0.05). The mean thickness of the tracheal cartilage was 0.12, 0.13, 0.19, and 0.32 mm in the control and the b-FGF groups, respectively, and showed a dose-dependent increase, which was statistically significant between the b-FGF 5 μg or 50 μg groups and the control group (p<0.01).

Conclusion: This study showed that slow-release b-FGF enlarges the tracheal lumen and thickens the cartilage in a dose-dependent fashion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cartilage / drug effects*
  • Cartilage / growth & development*
  • Fibroblast Growth Factor 2 / administration & dosage
  • Fibroblast Growth Factor 2 / pharmacology*
  • Rats
  • Rats, Wistar
  • Time Factors
  • Trachea / drug effects*
  • Trachea / growth & development*

Substances

  • Fibroblast Growth Factor 2